Skip to main content

Table 4 Univariate and multivariate analysis of variables associated with proliferative HCC

From: Three-dimensional multifrequency magnetic resonance elastography improves preoperative assessment of proliferative hepatocellular carcinoma

 

Univariate

Multivariate

 

OR (95% CI)

p value

OR (95% CI)

p value

Tumor c (m/s)

0.51 (0.27–0.95)

0.035*

0.15 (0.05–0.43)

 < 0.001*

Tumor φ (rad)

1.64 (0.31–8.63)

0.56

15.51 (1.09–219.97)

0.043*

Sex

Female

1 (Reference)

   

Male

0.93 (0.36–2.37)

0.87

  

Age

0.98 (0.95–1.01)

0.27

  

BMI

1 (0.9–1.11)

1.00

  

Size

0.91 (0.82–1.02)

0.07

  

AFP (ng/mL)

 ≤ 100

1 (Reference)

   

 > 100

1.11 (0.52–2.35)

0.80

  

Cirrhosis

Absent

1 (Reference)

   

Present

2.3 (1.07–4.95)

0.033*

3.13 (1.11–8.82)

0.031*

Hepatitis virus

Absent

1 (Reference)

   

Present

1.86 (0.63–5.49)

0.26

7.16 (1.59–32.25)

0.01*

Rim APHE

Absent

1 (Reference)

   

Present

4.55 (1.22–17.03)

0.024*

9.20 (1.88–45.04)

0.006*

Nonperipheral Washout

Absent

1 (Reference)

   

Present

1.05 (0.51–2.17)

0.89

  

Capsule

Absent

1 (Reference)

   

Present

0.64 (0.31–1.35)

0.24

  

Peritumoral enhancement

Absent

1 (Reference)

   

Present

1.76 (0.63–4.89)

0.28

6.074 (1.32–27.87)

0.02*

Tumor margin

Smooth

1 (Reference)

   

Non-smooth

1.86 (0.9–3.86)

0.094

2.98 (1.12–7.95)

0.029*

  1. OR odds ratio; CI confidence interval; BMI body mass index; A FPα-fetoprotein; APHE arterial phase hyperenhancement
  2. *Indicates statistically significant p values